Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III in Partial and Null Responders
Brief Summary: The purpose of this study is to demonstrate the efficacy of TMC435 in combination with peginterferon (PegIFN) + ribavirin (RBV) by means of establishing its non- inferiority compared to an approved regimen of telaprevir + PegIFN + RBV in patients who have previously failed PegIFN.


Options:
A: Arm Label: TMC435/PR; Type: EXPERIMENTAL; Interventions: Drug: TMC435 | Arm Label: TVR/PR; Type: ACTIVE_COMPARATOR; Interventions: Drug: TVR | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435/PR | Intervention Type: DRUG; Name: TVR; Assigned to Arm(s): TVR/PR
B: Arm Label: Part 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Copegus, Drug: Pegasys, Drug: Placebo | Arm Label: Part 1: RO5190591 300mg po; Type: EXPERIMENTAL; Interventions: Drug: Copegus, Drug: Pegasys, Drug: RO5190591 (Danoprevir) | Arm Label: Part 1: RO5190591 600mg po; Type: EXPERIMENTAL; Interventions: Drug: Copegus, Drug: Pegasys, Drug: RO5190591 (Danoprevir) | Arm Label: Part 1: RO5190591 900mg po; Type: EXPERIMENTAL; Interventions: Drug: Copegus, Drug: Pegasys, Drug: RO5190591 (Danoprevir) | Arm Label: Part 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Copegus, Drug: Pegasys, Drug: Placebo | Arm Label: Part 2: RO5190591 300mg po; Type: EXPERIMENTAL; Interventions: Drug: Copegus, Drug: Pegasys, Drug: RO5190591 (Danoprevir) | Intervention Type: DRUG; Name: Copegus; Assigned to Arm(s): Part 1: Placebo, Part 1: RO5190591 300mg po, Part 1: RO5190591 600mg po, Part 1: RO5190591 900mg po, Part 2: Placebo, Part 2: RO5190591 300mg po | Intervention Type: DRUG; Name: Pegasys; Assigned to Arm(s): Part 1: Placebo, Part 1: RO5190591 300mg po, Part 1: RO5190591 600mg po, Part 1: RO5190591 900mg po, Part 2: Placebo, Part 2: RO5190591 300mg po | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 1: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part 2: Placebo | Intervention Type: DRUG; Name: RO5190591 (Danoprevir); Assigned to Arm(s): Part 1: RO5190591 300mg po | Intervention Type: DRUG; Name: RO5190591 (Danoprevir); Assigned to Arm(s): Part 1: RO5190591 600mg po | Intervention Type: DRUG; Name: RO5190591 (Danoprevir); Assigned to Arm(s): Part 1: RO5190591 900mg po | Intervention Type: DRUG; Name: RO5190591 (Danoprevir); Assigned to Arm(s): Part 2: RO5190591 300mg po
C: Arm Label: PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a, Drug: Placebo | Arm Label: Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a, Drug: Telaprevir | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a, Drug: Telaprevir | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week; Type: EXPERIMENTAL; Interventions: Drug: Pegylated Interferon Alfa 2a, Drug: Telaprevir | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week | Intervention Type: DRUG; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week
D: Arm Label: LDV/SOF 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF 12 weeks, LDV/SOF 24 weeks, LDV/SOF+RBV 12 weeks, LDV/SOF+RBV 24 weeks | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV 12 weeks, LDV/SOF+RBV 24 weeks

Answer: A